SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Frederick Law Olmsted — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientFrederick Law Olmsted
Date of birth1822-04-26
IdentifiersMRN HR-NI022-SYN-TD; SSN (made up) 000-22-5519
Document date1895-08-04
AuthorNathan Calder, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month dementia review. [S]

History of Present Illness

Mr. Olmsted returns with his caregiver three months after his first visit, nine weeks after starting donepezil 5 mg each morning. He has had no nausea, diarrhea, loss of appetite, dizziness, fainting, or vivid dreams. His caregiver feels he is a little more engaged in the mornings, and his memory is otherwise unchanged. The night-time confusion during his cold three weeks ago stopped as soon as the diphenhydramine cold medicine was stopped, and his cough has gone. He stopped driving after the consultation and walks with company most days. He wears a medical identification bracelet. His caregiver completed the Zarit Burden Interview today and describes broken sleep, worry about leaving him alone, and little time off. [S]

ElementDetail
MedicineDonepezil 5 mg for nine weeks; no side effects
CourseMemory unchanged; slightly more engaged in the mornings
Interval illnessCold with night-time confusion from diphenhydramine three weeks ago, resolved
SafetyNo driving; medical identification bracelet; no wandering
CaregiverZarit Burden Interview 24; broken sleep and little time off

Review of Systems

SystemResultFinding
GastrointestinalNegativeNo nausea, diarrhea, or loss of appetite
CardiovascularNegativeNo fainting or lightheadedness
NeurologicalPositiveMemory loss unchanged; no night-time confusion since the antihistamine was stopped
PsychiatricNegativeMood steadier; no hallucinations or agitation

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Donepezil 5 mg oral tablet, one tablet by mouth each morningOne tablet by mouth each morning with breakfastOral route1895-06-02 to 1895-08-04completedS
Donepezil 10 mg oral tablet, one tablet by mouth each morningOne tablet by mouth each morning with breakfastOral route1895-08-04activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1895-08-04Body height175cmS
1895-08-04Body weight71.2kgS
1895-08-04Body mass index (BMI) [Ratio]23.2kg/m2S
1895-08-04Systolic blood pressure128mm[Hg]S
1895-08-04Diastolic blood pressure76mm[Hg]S
1895-08-04Heart rate62/minS
1895-08-04Respiratory rate14/minS
1895-08-04Body temperature36.6CelS
1895-08-04Oxygen saturation in Arterial blood by Pulse oximetry97%S

Physical Exam

Vital signs recorded on 1895-08-04; see the Vital Signs section. [S]

SystemFinding
GeneralAlert, pleasant, and engaged
CardiovascularRegular rhythm at 62 per minute; blood pressure 128/76 mmHg; weight 71.2 kg
NeurologicalOriented to person and place, not to date; no new focal signs; normal gait

Problems

ProblemClinical statusVerificationCodeProvenance
Mild dementia (major neurocognitive disorder), progressive, amnestic-predominant with executive difficulty, type undetermined; CDR global 1activeconfirmed F03.A0S — Synthetic modern coding of his documented failing memory; the cause is unknown, so the type is left unspecified. Stage and scores are synthetic.
Common cold, with two nights of increased confusion after an over-the-counter nighttime cold medicine containing diphenhydramine; resolvedresolvedconfirmed J00S — Synthetic intercurrent illness at an unscheduled visit; it does not echo a documented illness.
Progressive memory loss over about two years with decline in managing his work and affairs, under evaluation for dementia or mild cognitive impairmentresolvedconfirmed R41.3S — Synthetic presenting concern at the index visit, superseded by the dementia diagnosis at the four-week visit; the failing memory is documented (D).

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Medication safetyMedication review with the AGS Beers Criteria (anticholinergic burden, sedatives, sleeping pills, antipsychotics)Every visitCompleted todayDiphenhydramine cold medicine stopped after the sick visit; no anticholinergic or sedating drugs now
SurveyNeuropsychiatric symptom screen (NPI-Q)Every visitCompleted todayMild apathy, less in the mornings; no hallucinations, agitation, or wandering; the night-time confusion has not recurred
Medication safetyCholinesterase inhibitor tolerability and benefit: heart rate, fainting, nausea, diarrhea, weight, sleep and dreamsEach follow-up on treatmentCompleted todayOn 5 mg for nine weeks: heart rate 62, no fainting, no gastrointestinal effects, weight 71.2 kg (down 0.6 kg), no vivid dreams; increasing to 10 mg
Medication safetyAntipsychotic appropriateness and taper reviewEvery visit if on an antipsychoticNot indicatedNot on an antipsychotic
ExaminationVascular risk-factor control (blood pressure, lipids, glucose, smoking)Every visitCompleted todayBlood pressure 128/76 mmHg; lipids at the wellness visit
ExaminationHome safety evaluationAt diagnosis and each follow-upDeferredThe home safety checklist given at diagnosis was not reviewed at this visit, a deviation from the each-follow-up item. There have been no falls, burns, or wandering, so no harm is evident. Corrective action: the checklist is reviewed at the six-month visit
SurveyCognitive test (MoCA)Annually; every visit if a change is reportedUp to dateMoCA 19 three months ago; no change reported
SurveyADL (Katz) and IADL (Lawton-Brody)Annually, and at any reported changeUp to dateNo change reported since the first visit
SurveyDementia stage (CDR or FAST)AnnuallyUp to dateCDR 1 two months ago
SurveyDepression screen (PHQ-9)Annually, and at any reported changeUp to datePHQ-9 6 three months ago; mood steadier today
ExaminationFall-risk assessment (Timed Up and Go, gait and balance)AnnuallyUp to dateNo falls; Timed Up and Go 11 seconds three months ago
ExaminationDriving safety (CDR-based)At diagnosis and annuallyCompleted todayNo driving since the consultation
Self-managementFirearms, wandering, and financial safetyAt diagnosis and with any changeCompleted todayNo firearms; medical identification bracelet worn; no wandering; caregiver oversees finances
SurveyCaregiver burden (Zarit Burden Interview) and caregiver needsAt diagnosis, then every 6 to 12 monthsCompleted todayZarit Burden Interview 24, moderate burden (21 or more): education, adult day program, and respite information given; the item missed at diagnosis is now done
Self-managementAdvance care planning and goals of careAt diagnosis, then annually and at stage changesCompleted todayHealth care agent named and his values and wishes recorded today, with him taking full part
LaboratoryTSH, vitamin B12, blood count, and metabolic panelAt diagnosis; repeat only with acute cognitive worseningUp to dateNormal at diagnosis; no acute change to repeat them
LaboratorySyphilis and HIV testingOnly with risk factors or atypical featuresNot indicatedNo risk factors
ImagingStructural brain MRI, non-contrastOnce at diagnosis; repeat only with an atypical course or focal changeUp to dateDone once at diagnosis; no atypical course
LaboratoryAmyloid or tau biomarkers (blood, CSF, or amyloid PET) and APOE genotypeBefore anti-amyloid therapy, or when the result would change careNot indicatedDeclined two months ago; no change in his wishes
ImagingAnti-amyloid antibody therapy with ARIA surveillance MRIOnly if anti-amyloid therapy is startedNot indicatedNot chosen
Self-managementLifestyle: aerobic exercise about twice a week, hearing, vision, sleep, social engagementOngoingCompleted todayWalks most days with company; adult day program will add social contact
ReferralDementia care navigation and caregiver support programAt enrollment, with ongoing supportCompleted todayCaregiver education program and adult day program arranged
Self-managementVaccination status (influenza, pneumococcal, zoster, COVID-19, Tdap)Yearly, per the CDC scheduleDueAt the wellness visit in about six weeks

Goal progress:

Guideline basis: Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology (2001); Practice parameter update: evaluation and management of driving risk in dementia: report of the Quality Standards Subcommittee of the American Academy of Neurology (2010); Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care (2025); American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023); CMID: Clinical Monitoring Intelligence Database, Non-Alzheimer's dementia and Alzheimer's disease monographs (2026)

Follow-up: Annual wellness visit in about six weeks. Six-month dementia review in about three months. Next scheduled visit 1895-09-15: subsequent annual wellness visit. [S]